BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 26731822)

  • 1. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of blood stream infections in pediatric patients at a Tertiary Care Cancer Centre.
    Thacker N; Pereira N; Banavali SD; Narula G; Vora T; Chinnaswamy G; Prasad M; Kelkar R; Biswas S; Arora B
    Indian J Cancer; 2014; 51(4):438-41. PubMed ID: 26842152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
    Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
    Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization and risk factors for carbapenem-resistant Gram-negative bacilli colonization in children: emergence of NDM-producing Acinetobacter baumannii in a newborn intensive care unit in Turkey.
    Karaaslan A; Soysal A; Altinkanat Gelmez G; Kepenekli Kadayifci E; Söyletir G; Bakir M
    J Hosp Infect; 2016 Jan; 92(1):67-72. PubMed ID: 26601601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria.
    Garg A; Garg J; Kumar S; Bhattacharya A; Agarwal S; Upadhyay GC
    Indian J Med Res; 2019 Feb; 149(2):285-289. PubMed ID: 31219096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
    Dong SX; Wang JT; Chang SC
    J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.
    Lee JY; Kang CI; Ko JH; Lee WJ; Seok HR; Park GE; Cho SY; Ha YE; Chung DR; Lee NY; Peck KR; Song JH
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6673-6678. PubMed ID: 27572416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: Risk factors and outcome.
    Ozsurekci Y; Aykac K; Cengiz AB; Basaranoglu ST; Sancak B; Karahan S; Kara A; Ceyhan M
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):359-364. PubMed ID: 28089138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antimicrobial activity of "last-resort" antibiotics against unusual nonfermenting Gram-negative bacilli clinical isolates.
    Jacquier H; Le Monnier A; Carbonnelle E; Corvec S; Illiaquer M; Bille E; Zahar JR; Jauréguy F; Fihman V; Tankovic J; Cattoir V;
    Microb Drug Resist; 2012 Aug; 18(4):396-401. PubMed ID: 22335615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin Susceptibility Testing by Colistin Broth Disk Elution MIC Method among Carbapenem-resistant Gram-negative Blood Culture Clinical Isolates in a Tertiary Care Setting, East Delhi, India.
    Nirmal K; Singh NP; Sarkar K; Goyal N; Gangar S; Dwivedi AN
    Ethiop J Health Sci; 2023 Sep; 33(5):743-750. PubMed ID: 38784504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surveillance of resistance in the intensive care units using a cumulative antibiogram].
    Yürüyen C; Daldaban Dinçer Ş; Yanılmaz Ö; Boz ES; Aksaray S
    Mikrobiyol Bul; 2018 Oct; 52(4):329-339. PubMed ID: 30522419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Paul M; Carmeli Y; Durante-Mangoni E; Mouton JW; Tacconelli E; Theuretzbacher U; Mussini C; Leibovici L
    J Antimicrob Chemother; 2014 Sep; 69(9):2305-9. PubMed ID: 24872346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center.
    Huang YC; Wu PF; Lin YT; Wang FD
    J Microbiol Immunol Infect; 2019 Apr; 52(2):304-311. PubMed ID: 30097388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
    Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).
    Mataseje LF; Bryce E; Roscoe D; Boyd DA; Embree J; Gravel D; Katz K; Kibsey P; Kuhn M; Mounchili A; Simor A; Taylor G; Thomas E; Turgeon N; Mulvey MR;
    J Antimicrob Chemother; 2012 Jun; 67(6):1359-67. PubMed ID: 22398651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
    Gibson GA; Bauer SR; Neuner EA; Bass SN; Lam SW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):431-6. PubMed ID: 26525802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide surveillance of antimicrobial resistance among clinically important Gram-negative bacteria, with an emphasis on carbapenems and colistin: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2018.
    Lee YL; Lu MC; Shao PL; Lu PL; Chen YH; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Liao MH; Hsueh PR
    Int J Antimicrob Agents; 2019 Sep; 54(3):318-328. PubMed ID: 31202925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.